Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Real news from GBM...
https://greenbatteryminerals.com/news/
Yingling, President and CEO of Green Battery, states, “I am very pleased to announce that we have successfully created graphene-containing Lithium-ion Batteries using graphite from our Berkwood Graphite Quebec property. Graphene-containing LIBs have shown to be far superior to traditional LIB. I am even more excited that we have discovered a proprietary technique with Graphene Star whereby we can build these batteries in an entirely environmentally friendly way without using any chemicals, emissions, pollution or cause waste. A graphene battery is superior on so many points and is better for the environment. The battery itself also costs significantly less to create, which can offer huge savings.
We look forward to the potential joint venture with Graphene Star and developing a next-generation graphene-containing lithium-ion battery.”
Lets get this rolling ASAP. 63% of Neuro is held by AGN.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/173/algernon-neuroscience-doses-first-subject-in-phase-1-dmt
Yep, if an investor never sells or sells at a loss or doesn't buy as the price fluctuates depending on successes or market changes, like COVID/BTH/current changes, then.?. Hmmm.@#/?.
Holding a core and thinking ahead seems a fair strategy, IMO. ..
Buy low, sell higher.?. Accept personal decisions. Speculative investments?
At Ease, Plz...
...GLTA...
AGN: "is pleased to announce that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3 of 2023."
"The planned study design will include the following elements:
Multinational, three-arm, randomized, double-blind, placebo-controlled trial to evaluate NP-120 in approximately 180 patients.
Patients will be randomized 1:1:1 to receive NP-120 (20mg TID) or NP-120 (40mg TID), or placebo for 12 weeks.
The primary endpoint will be the reduction in geometric mean 24-hr cough count over 12 weeks compared to placebo.
Secondary endpoints will include safety, tolerability and patient-reported quality-of-life measures.
"The design of Phase 2 studies in chronic cough have been validated in trials conducted by Merck & Co and Bellus Health,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “By mirroring the design of those studies, Algernon will have a direct benchmark for comparison and, if successful, a clear regulatory path for Ifenprodil for the treatment of chronic cough.”
...GLTA...
"AGN Neuro has filed a Form 1-A offering statement with the U.S. Securities and Exchange Commission (the “SEC”), seeking qualification to raise up to USD $10M for AGN Neuro by offering up to 37.5% of its common shares, (including the maximum amount of bonus shares) with majority ownership residing with AGN Pharma, under a Tier II Regulation A+ offering (Reg A+). The capital raised will be used for research, development, and program management costs related to the completion of a Phase 1 and Phase 2a DMT stroke study"
What does this mean for AGN common shareholders?
AGN Neuro / CHDR ?.
Creating 13M shares for Neuro and selling 37% while 63% remains under AGN?
Will the supposed added value support the IPF work at AGN, "to be announced shortly"?
Are there lined up buyers?
As a private sub of AGN how will this all affect us, the long term shareholders and do we get a vote on this proposal/initiative?
What specifically is the overall plan and benefits for AGN common shareholders?
Bonus shares?
Is this supported by current PP holders? Shareholders?
More info Please, with a specific plan ?
OAN: Oregon has passed and is implementing the clinical use of 'shrooms"/etc,
...GLTA...
The company web site has the ODD approval, First patient for the DMT trials but no stock opinions...***.
Lets all hope for big things in the New Year with the possibilities we invested in this Speculative venture to be involved in...Merry new year...GLTA...
https://ir.algernonpharmaceuticals.com/
ifenprodil FDA ODD should be significant soon, we hope. and
I had not seen the official registration of the DMT CT but here it is;
https://www.clinicaltrials.gov/ct2/show/NCT05559931?term=DMT&draw=2&rank=5
Merry New Year to All.
...GLTA...
Yes, Sure nice to see AGN's IPF drug has receiver OD Designation. AGN's,DMT trials have cash to proceed Phase 1, asap please. 3 drugs in Clinical Trials during 2023.!..New PP after strong News possible.?. First Q, 2023.?.
Yes, Winners/Wannabees/losers attempt to write/rewrite history or distort reality... reasons profit/power.?. . Selling a spec stock at the bottom? whatever...
Neo natzy rumor links from1990s, LMAO,. what does that have to do with AGN now?. @#Drivel?.
MORE? @$1.80 a share? <+< soon, imhfo.
We welcome back any 'True' incite/insight.
MERRY NEW YEAR TO ALL
...GLTA...
I am not impressed by the couple paragraph inadequate descriptions of our company's progress that we usually see in the monthly reports. It would seem to me that quite a bit more effort should be put into these reports with so much actually going on. These bare minimum efforts to present the company's progress have to improve in content and quality, JMHFO...
Maybe we could even see some continued share price recovery with a professional looking effort...GLTA...
Looks like a good presentation at the Wonderland Conference from C Moreau and R Strassman...
...GLTA...
https://algernonpharmaceuticals.com/wp-content/uploads/2018/01/Wonderland-Algernon-Christopher-Moreau-Science-Keynote-PPT-FINAL-For-Nov-5th.pdf
Wonderland:
AGN's subject presentations,
CEO C Monreau 12:50 to 1:30, Nov 4, Business; Stroke Clinical
Trials
Dr. Strassman 1:15 to 2:00, Nov 5, Science; Stroke
Check out the hundreds of attendees, speakers and Many subjects and panelists for each. Looks well organized and a pretty B-F-D, IMHFO...
BTW, check out the ticket pricing, maybe we'll make a profit on this gig. LOL.
https://microdose.buzz/wonderland/agenda
...GLTA...
IS the AGN formulation and MOU to be part of this existing CT with D'Sauza? At Yale? Primary Completion 12 - 2023?
...GLTA...
https://www.clinicaltrials.gov/ct2/history/NCT04711915?V_7=View#StudyPageTop
IS the AGN formulation and MOU to be part of this existing CT with D'Sauza? At Yale? Primary Completion 12 - 2023?
...GLTA...
https://www.clinicaltrials.gov/ct2/history/NCT04711915?V_7=View#StudyPageTop
AGN is targeting Stroke treatment with a sub hallucinogenic dose as seen at the CRL pre clinical work, IMO...GLTA...
https://www.globenewswire.com/en/news-release/2021/11/01/2324220/0/en/Algernon-Pharmaceuticals-Establishes-6-hours-as-Optimum-Treatment-Period-for-DMT-in-Neuron-Study.html
Algernon will be using a microdose and we dont know the doses at yale, so most likely way different Trials. It's good that Yale is using the AGN formulation, IMO. The Yale Phase 2 is separately sponsored and a probably much longer and bigger Trial than the microdose work at AGN/CHDR.
Good to see acceptance from other's and some progress.
Couple weeks to Wonderland...GLTA...
Does this imply that the CHRD Phase 1 is now changed to a Phase 2 at Yale using AGN's drug and MOU? Hmmmm,...GLTA...
Come on Mr Monroe and team AGN, let's see the CHDR Phase 1 Trial process started asap. You all need some progress to report at this conference with Mr Strassman.
https://chdr.nl/clinical-studies-development/trial-services/recruitment
...GLTA...
An interesting read from Dr Strassman. He seems supportive of the DMT microdose theories and against large doses and the use of other psychedelic's like LSD/5 me-0. IMO.
Nice to see AGN as the posterboard company for having a valid plan for use of the microdose concept. Seeing Dutch scientists' referenced in this article shows AGN is doing their initial Phase 1 dosing Clinical Trial in an appropriate venue.
Lets get going AGN, asap. $1.5M in the bank... 3.3m fully diluted. No debt.
...GLTA...
You so funny.
Don't invest here, I don't care. com.
Sell short, I don't care.com.
Open forum opinions without valid links, I don't care.com.
Maybe,
View the FDA link I posted...GLTA...
Link please...
Your "opinion" is wrong...
Maybe reread what the FDA says...50% tax credit, no fees, GRANTS...
...GLTA...
Please dont have to call me Sir, I was a mostly PFC and made Corporal 3 times, LOL...Read what I write not what you want to see...
""- Seven-year marketing exclusivity to the first sponsor obtaining FDA approval of a
designated drug
- Tax credit equal to 50% of clinical investigation expenses
- Exemption/Waiver of PDUFA application (filing) fees
- Assistance in the drug development process
- Orphan Products Grant funding
Eligibility A previously unapproved drug may be eligible for orphan drug status if it meets
the definition of an orphan drug and is:
- A previously unapproved drug
- A new orphan indication for an approved drug
- The “same drug” as one already approved but with a potential to be “clinically superior”
https://www.fda.gov/media/83372/download
"Although there is no regulatory review deadline for these products, the FDA currently aims to review 75% of all orphan designation requests within 90 days of receipt. In her recent blog post, Dr. Rao states that the Agency strives “to review these requests in an efficient and timely manner because we understand how critical designation can be for companies to move forward with their drug development plans.” Dr. Rao notes that reviewing ODD applications in both an efficient and timely manner is still a top priority within the OOPD, “but to ensure we continue to conduct these reviews with the appropriate level of care and consideration, our current goal is to review on average 75% of designation requests within 120 days of receipt.”
So, possibly AGN will get an ODD answer by the EOY.
With Ifenprodil IPF/CC Clinical Trial history in Australia/NZ hospitals and the refunds AGN has benefited from, there seems to be a good chance the AGN.aus subsidiary, (with Dr Williams) might be the logical place for further work.
So#2, that may imply with the Now faster progress the DMT/Stroke research program is finally seeing, AGN might have BOTH of these Drugs' Trials dramatically moving forward by EOY.
Hmmmm. JMHO...GLTA...
Some funding for starting Phase 1 DMT in Holland? Possibly...GLTA...
https://finance.yahoo.com/news/algernon-pharmaceuticals-announces-receipt-cdn-110000044.html
Biggest Psychedelic Medical News EVER, IMHFO...
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Receives-Approval-for-Groundbreaking-Phase-1-DMT-Human-Stroke-Study?id=372049
This seems to be the possibly Best developement in the entire psychedelic sector, IMO. A Golden Ticket?
...GLTA...
"The Company has now completed its intravenous formulation (“IVF”) that will be used in the Phase 1 DMT study. The formulation was developed by the Centre for Human Drug Research (“CHDR”) and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands. The Company has applied for ethics and clinical trial approval and is expecting to have a response shortly."
https://www.globenewswire.com/news-release/2022/09/08/2512310/0/en/Algernon-Pharmaceuticals-Secures-Lead-Sponsorship-of-2022-Wonderland-Psychedelic-Conference-in-Miami.html
Yes, here is the Golden Ticket...IMO...GLTA...
"The Company has now completed its intravenous formulation (“IVF”) that will be used in the Phase 1 DMT study. The formulation was developed by the Centre for Human Drug Research (“CHDR”) and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands. The Company has applied for ethics and clinical trial approval and is expecting to have a response shortly."
meant to post the long version with 'Ring the Bell' drum solo.
https://www.bing.com/videos/search?q=elp+karn+evil+9+live+long+version&&view=detail&mid=0C30EF010D7D1E7E84DB0C30EF010D7D1E7E84DB&&FORM=VRDGAR&ru=%2Fvideos%2Fsearch%3Fq%3Delp%2520karn%2520evil%25209%2520live%2520long%2520version%26qs%3Dn%26form%3DQBVDMH%26%3D%2525eManage%2520Your%2520Search%2520History%2525E%26sp%3D-1%26pq%3Delp%2520karn%2520evil%25209%2520live%2520long%2520version%26sc%3D0-33%26sk%3D%26cvid%3D730D9E445F2245449EABF072B8A26C49%26ghsh%3D0%26ghacc%3D0%26ghpl%3D
Now that management has shares that would seem likely after some DMT news and IND for Ifenprodil. They could possibly head to the NASDAQ and an IPO, 3+ for 1? Reward long time shareholders and PP investors. The show may finally start...GLTA...
https://www.bing.com/videos/search?q=elp+karn+evil+9+live&view=detail&mid=301D7183C43FB309998E301D7183C43FB309998E&FORM=VIRE0&ru=%2fsearch%3fq%3delp%2bkarn%2bevil%2b9%2blive%26form%3dANNTH1%26refig%3d5fcfc43f486c4a64a27353f72105eb97%26sp%3d5%26qs%3dAS%26pq%3delp%2bkarn%26sk%3dPRES1AS4%26sc%3d8-8%26cvid%3d5fcfc43f486c4a64a27353f72105eb97
Hi tiger, another spac, so I maybe guessed right. LMA pre/post SLB deal and R/S as I've been here forever. Nice turn around and strong possibilities with Voraxial separators now that enough time has past. Thats speculative investing ...GLTA...
Good, AGN closed the Private placement. Pay CHDR and get the Microdose DMT stroke CT started.
Recent Video has CM saying at least two assets will be in Phase 2, in 2023, Stroke and CKD.
AGN's best drug, Ifenprodil wasn't discussed in this video. Maybe something bigger.?.
Long time speculative investors have some positive stuff happening, finally. IMHFO...GLTA...
Everyone makes their own decisions. It's just/sort of like Vagas. Sometimes a person's hunch or speculation or patience succeeds, sometimes not, no matter how much they studied or thought things would go.
Can't complain much. Except maybe to eventually have to explain/complain to a wife or husband and That also has issue$, depending/sort of. LOL. M$?
What's next for AGN and it's Long time shareholders and possible new speculative investors. I guess thar's the pertinent question.
It's good to see the CEO waiting for apparently positive news and demand for AGN shares. Hopefully soon, "couple weeks '...
Buy/bet, sell/fold, hold/'em. LOL...GLTA...
'A couple weeks for full IPF/CC data'. DMT microdose Phase 1 'on track'. although we wanted that all done 6 months ago.
Aiming for '$50M MC/($25 a share) as they release (assumed) positive future news. Apparently not planning another near term PP. Possibly an offering in conjunction with news and NASDAQ up-list, IMO. I expect AGN to start a PR push after Memorial Day... Finally...
Making decisions for today's AGN. BTH is long dead, along with the acute treatment for COVID. Long term Longs bet on those. The future starts again...GLTA...
Yes, not having 'stellar results' for the acute disease of COVID 19 and the delayed success we now FINALLY see with chronic diseases IPF and CC was an almost lethal combo.
One respected investor/poster bought $3M worth just before 12-15-20. Another called it right after 'trends' were seen instead of 'significance'. High risks and decisions for ALL....
Got to agree though that there are strong possibilities for AGN as a 'speculative buy' now. $25 could make it good. If we get there and the stars align???GLTA...
"very good news for the company". CEO AGN...GLTA...
https://algernonpharmaceuticals.com/?msclkid=0bd27ea6ba7d11ecba9308c4db45103f
..
We all bet here in the past. It is still up to continued efforts by the Company towards a strong future and personal decisions of current and new/prospective shareholders.
One developing drug, Ifenprodil for IPF/CC and cancer tumors. Licensed IP and phase 1+ for new paths with microdosed DMT for stroke treatment. . .
COVID authorities in Australia may be open to long term lung care medications for IPF/CC. There are many with long COVID lung symptoms and a supportive Ausie Clinical Trial system.
...GLTA...
I agree that these are pretty good results for a 12 week treatment. Recovering from lung damage takes a long time, as with smokers. I hope we see some comparisons to other drugs for CC/IPF.
Too many folks have smoked too long and too much. Seems like an important medical market to target...GLTA...
"How much does lung capacity increase after quitting smoking?
People that quit smoking lung capacity can improve by 10% in just 9 months...